Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia

This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Binglei, Chen, Lingyun, Zhou, Jian, Zu, Yingling, Gui, Ruirui, Li, Zhen, Wang, Juan, Yu, Fengkuan, Zhang, Yanli, Zhao, Huifang, Ji, Zhenyu, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/
https://www.ncbi.nlm.nih.gov/pubmed/33875780
http://dx.doi.org/10.1038/s41598-021-88080-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/
https://www.ncbi.nlm.nih.gov/pubmed/33875780
http://dx.doi.org/10.1038/s41598-021-88080-3

Ejemplares similares